Ethical Challenges and Promises of Preexposure Prophylaxis (PrEP) for HIV Prevention

 

Ethical Challenges and Promises of Preexposure Prophylaxis (PrEP) for HIV Prevention

Introduction:

In the ongoing fight against the global HIV/AIDS pandemic, the introduction of preexposure prophylaxis (PrEP) has marked a significant milestone. In 2012, the US Food and Drug Administration (FDA) approved Emtricitabine/Tenofovir (Truvada) as the first drug for PrEP, offering a novel approach to reduce the risk of HIV transmission among high-risk individuals. This groundbreaking development has opened up a realm of possibilities in HIV prevention, but it also brings to the forefront a series of ethical challenges that must be navigated. This article delves into the ethical complexities and promises surrounding PrEP.

Behavior and Effectiveness:

Emtricitabine/Tenofovir has been shown to be only partially effective for HIV prevention. Clinical trials have demonstrated that it can reduce the risk of HIV transmission through sexual contact, but the level of effectiveness varies significantly based on adherence. High adherence can result in more than 90% protection, while overall adherence rates have shown a 44% reduction in HIV transmission. Though a 44% reduction is indeed a significant benefit, the critical factor is adherence. To maximize the effectiveness of PrEP, ongoing studies and interventions to improve adherence are necessary.

One ethical concern is whether PrEP could lead to behavioral disinhibition, meaning individuals may engage in riskier sexual behaviors due to a perceived safety net. Clinical trials, however, did not observe this phenomenon. The risk of increased unsafe sex behaviors exists, but it would require a substantial shift to offset the benefits of PrEP on a population level.

Cost-effectiveness:

One of the primary ethical concerns surrounding PrEP is its cost. Daily use of Emtricitabine/Tenofovir in the United States has been estimated at approximately $10,000 per year, including screening and physician visits. This cost is comparatively high when considering alternative prevention strategies. However, the cost-effectiveness equation changes when looking at the potential economic and health burdens of HIV infection. In essence, the high upfront cost of PrEP can be cost-effective when compared to the lifelong financial and health expenses associated with treating HIV infection.

The challenge for health systems is to determine the comparative cost-effectiveness of PrEP concerning different prevention approaches. Various models have explored when and for whom PrEP becomes cost-effective. It's crucial to consider these models to allocate resources wisely.

Patient and Population-Level Risk:

Another significant ethical challenge relates to the risk of drug resistance when HIV-infected individuals take Emtricitabine/Tenofovir for PrEP. Drug resistance can compromise therapeutic options and potentially pose a public health threat. As a result, PrEP requires regular testing and reliable medication use.

The FDA has the authority to impose stringent conditions for the prescription and dispensing of PrEP, such as requiring a negative HIV test result. However, such conditions could reduce access to PrEP. The FDA has instead chosen to recommend regular HIV testing, symptom monitoring, and training for healthcare professionals. Balancing access and safety is a challenge that must be addressed.

Equity and Justice:

While PrEP empowers patients and promotes public health, it could inadvertently exacerbate healthcare inequalities. The high cost and intensive medical monitoring required for PrEP may exclude individuals with low income, unstable housing, drug dependence, or mental illness. This challenge becomes even more pronounced in low-income countries with limited resources and infrastructure.

The early adopters of PrEP are likely to include individuals with greater education and resources, such as gay and bisexual men and heterosexual serodiscordant couples. Extending the benefits of PrEP to other vulnerable groups demands effective public health governance, research, and innovation.

Underserved Populations:

A vital aspect of addressing healthcare inequalities and promoting equity is reaching underserved populations with high HIV incidence. For instance, young black men who engage in male-to-male sexual contact are particularly at risk. While the Affordable Care Act may expand healthcare coverage, it cannot guarantee testing and PrEP for all vulnerable individuals. Prevention programs should explore synergies with HIV testing campaigns to link high-risk individuals with PrEP.

Women:

The FDA's approval of PrEP for women is noteworthy, as it addresses the need for a female-controlled prevention method. Although PrEP's effectiveness in women is less certain than in men, it remains essential due to the high percentage of new HIV infections occurring in women. Women need access to preventive methods that do not require a male partner's consent.

While PrEP's efficacy for women may be less certain, there is ongoing research into female-specific prevention methods like vaginal microbicides. The CAPRISA 004 trial, for example, found that topical tenofovir gel reduced HIV acquisition by 39% when used before and after sexual contact.

Generalized Epidemics:

In the global context, most new HIV infections occur in developing countries experiencing generalized epidemics. Although the United States was the first to approve PrEP, other countries may follow suit. The rollout of PrEP represents a critical test for governments, global health programs, and normative bodies. However, cost and healthcare infrastructure may pose significant barriers to widespread PrEP availability. Therefore, planning for regulatory review, financing, and implementation must continue on a global scale.

Ethical Resource Allocation:

A critical ethical question arises concerning resource allocation. Thousands of Americans living with HIV are currently on waiting lists for drug treatment, even though effective treatment significantly reduces the risk of transmission. Given limited resources, determining the relative priorities between PrEP for healthy individuals and treatment for currently infected individuals is challenging. Expanding treatment for all infected individuals while selectively offering PrEP to high-risk individuals is considered the best public health strategy, potentially leading to lower healthcare costs in the long term.

Ethical Research:

The FDA's approval of PrEP has triggered discussions about HIV prevention trials that use placebo controls. Beneficence requires researchers to minimize risks to study participants. Regulatory approval signals a strong evidence base, which can shift clinical norms. Offering PrEP to study participants, however, poses scientific and logistical research challenges, with no clear consensus on how to balance conflicting obligations. Multistakeholder deliberations should proceed on this topic.

Looking Ahead:

The approval of daily oral Emtricitabine/Tenofovir is just the beginning of PrEP interventions that will reach the market. Researchers are exploring alternative dosing schedules, such as intermittent PrEP taken before and after sexual exposure or during periods of increased sexual activity. Longer-acting PrEP products, such as vaginal rings or injectable agents, could also reduce the daily burden for PrEP users.

With these biomedical advances, PrEP could potentially transform HIV prevention, much like hormonal contraception transformed family planning. The combination of prevention strategies and universal treatment offers the possibility of an "AIDS-free" generation. These advancements are exciting, but they come with significant ethical considerations that must be addressed as we move forward.

Conclusion:

The introduction of preexposure prophylaxis (PrEP) for HIV prevention has marked a pivotal moment in the fight against.

JAMA. 2012;308(4):387-402.

VIEWPOINT

868 JAMA, September 5, 2012—Vol 308, No. 9